Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities.

摘要: The immunosuppressive combination most commonly used in de novo kidney transplantation comprises a calcineurin inhibitor (CI), tacrolimus, mycophenolic acid derivative and steroids. evidence which underlies this practice is based the Symphony trial with controlled follow-up of one year, no comparator group included CI-mTOR inhibitor. Different high-quality clinical trials support use everolimus as standard drug associated reduced exposure CI transplantation. This could improve health related outcomes recipients. The present recommendations constitute an attempt to summarise scientific supporting practice, discuss false beliefs, myths facts, offer specific guidelines for safe use, avoiding complications.